European Commission approves Tepmetko (tepotinib) for patients with advanced NSCLC with METex14 skipping alterations

Merck KGaA

18 February 2022 - Approval is based on Phase II results from VISION, the largest interventional study to date of patients with advanced NSCLC with METex14 skipping alterations.

Merck today announced that the European Commission has approved once-daily oral Tepmetko (tepotinib) as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Read Merck press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Europe